- Home
- OLMA vs AURA Comparison
OLMA vs AURA Comparison
Compare OLMA & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLMA
- AURA
- Stock Information
- Founded
- OLMA 2006
- AURA 2007
- Country
- OLMA United States
- AURA United States
- Employees
- OLMA N/A
- AURA N/A
- Industry
- OLMA Biotechnology: Pharmaceutical Preparations
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- OLMA Health Care
- AURA Health Care
- Exchange
- OLMA Nasdaq
- AURA Nasdaq
- Market Cap
- OLMA 289.0M
- AURA 370.1M
- IPO Year
- OLMA 2020
- AURA 2021
- Fundamental
- Price
- OLMA $4.67
- AURA $5.80
- Analyst Decision
- OLMA Strong Buy
- AURA Strong Buy
- Analyst Count
- OLMA 3
- AURA 4
- Target Price
- OLMA $27.67
- AURA $22.75
- AVG Volume (30 Days)
- OLMA 902.4K
- AURA 179.1K
- Earning Date
- OLMA 05-16-2025
- AURA 05-20-2025
- Dividend Yield
- OLMA N/A
- AURA N/A
- EPS Growth
- OLMA N/A
- AURA N/A
- EPS
- OLMA N/A
- AURA N/A
- Revenue
- OLMA N/A
- AURA N/A
- Revenue This Year
- OLMA N/A
- AURA N/A
- Revenue Next Year
- OLMA N/A
- AURA N/A
- P/E Ratio
- OLMA N/A
- AURA N/A
- Revenue Growth
- OLMA N/A
- AURA N/A
- 52 Week Low
- OLMA $2.86
- AURA $4.84
- 52 Week High
- OLMA $16.62
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- OLMA 50.50
- AURA 49.99
- Support Level
- OLMA $4.35
- AURA $4.94
- Resistance Level
- OLMA $5.74
- AURA $6.29
- Average True Range (ATR)
- OLMA 0.40
- AURA 0.44
- MACD
- OLMA -0.02
- AURA 0.05
- Stochastic Oscillator
- OLMA 25.26
- AURA 63.97
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.